RxDoctor Payments Data

Iva Tirres

Nurse Practitioner · Phoenix, AZNPI 1558972752

Payments from drug & device makers

$4,708in general payments, 2019–2025

Across 193 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$946
  • Xeris Pharmaceuticals, Inc.$388
  • Insulet Corporation$320
  • Recordati_rare_diseases_inc.$266
  • Lilly USA, LLC$261
  • Novo Nordisk$250
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$66814%
  • Food & beverage$4,04086%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,708 in reported general payments places this provider in the 90th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$22,876
Medicare patients
99
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$46,291
JardianceEmpagliflozin14$18,017
Tresiba Flextouch U-200Insulin Degludec11$11,852
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$11,693
Tresiba Flextouch U-100Insulin Degludec19$10,757
FarxigaDapagliflozin Propanediol11$8,538
JanuviaSitagliptin Phosphate11$7,296
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,555
Humalog Kwikpen U-100Insulin Lispro14$2,738
SynthroidLevothyroxine Sodium13$991
Hydrocortisone14$614
Methimazole19$302
Levothyroxine Sodium48$284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$250$46,29134 claims
Boehringer IngelheimJardiance$34$18,01714 claims
AstraZenecaFarxiga$244$8,53811 claims
AbbVieSynthroid$222$99113 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$109$28448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →